Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Cash from Operations (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Cash from Operations for 11 consecutive years, with 1900106.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 59.6% to 1900106.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 12014081.0 through Dec 2025, down 10.12% year-over-year, with the annual reading at 12014081.0 for FY2025, 10.12% down from the prior year.
  • Cash from Operations for Q4 2025 was 1900106.0 at Marker Therapeutics, up from 2735876.0 in the prior quarter.
  • The five-year high for Cash from Operations was 1197499.0 in Q3 2024, with the low at 12226062.0 in Q1 2022.
  • Average Cash from Operations over 5 years is 4407880.45, with a median of 4403398.5 recorded in 2022.
  • The sharpest move saw Cash from Operations crashed 2158.86% in 2023, then surged 117.35% in 2024.
  • Over 5 years, Cash from Operations stood at 4858123.0 in 2021, then grew by 15.53% to 4103662.0 in 2022, then surged by 42.31% to 2367584.0 in 2023, then plummeted by 98.65% to 4703135.0 in 2024, then soared by 59.6% to 1900106.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 1900106.0, 2735876.0, and 1878362.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.